Engage Early To Assess Possible Referral Outcomes, Generics Firms Advised
This article was originally published in SRA
Executive Summary
Drug companies should ensure early involvement of their regulatory affairs personnel in EU referral procedures to help anticipate possible outcomes and facilitate their smooth implementation. There have been examples recently where the burden of implementing certain referral outcomes such as conducting additional post-authorization studies, has led companies, especially generic manufacturers, to withdraw their marketing authorization rather than comply with the new obligations, reports Vibha Sharma.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.